PATENT CLAIM ANALYSIS

Application Number: 16235858
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["424", "093450"]

Abstract:
The present invention relates to the identification of a group of microorganisms, which are relatively abundant in the microbial communities associated with fruits and vegetables typically consumed raw and therefore transient or permanent members of the human microbiota. The consumption of mixtures of these microbes at relevant doses will produce a beneficial effect in the host by reducing the propensity to diabetes, obesity and metabolic syndrome mediated in part by production of short chain fatty acids to enhance colonic butyrate production. Therapeutic methods of the invention involve the use of live microorganisms or metabolites derived from said microorganisms to establish a microbial composition in the mammalian host that will improve significantly the ability to control weight, reduce the onset of diabetes, obesity and metabolic syndrome, and improve overall health.

Claim (Index 20):
A synthetic consortium of microbes comprising at least two microbial entities, selected from bacteria and fungi, whose genomes are defined, such that it is possible to predict production of short chain fatty acids by unconstrained genome-wide metabolic models, based upon genes contained in the genomes of said microbial entities, and wherein said models predict a synergistic interaction and/or higher short chain fatty acid production when said microbial entities are combined and/or grown on prebiotic polysaccharides, as compared to short chain fatty acid production of the microbial entities grown in isolation and/or grown in rich medium, wherein the predictions of the genome-wide metabolic model are tested and validated by experimentally quantifying the production of short chain fatty acids of the at least two microbial entities in isolation and/or grown in rich medium and grown together and/or grown on prebiotic polysaccharides, and wherein the synthetic consortium is formulated to be administered to an animal in an amount effective to improve at least one of diabetes and fasting blood glucose, glucose tolerance, insulin sensitivity, HbA1c, and/or HOMA-IR compared to levels found in a subject treated with an antidiabetic therapy alone and wherein at the least 2 microbial entities have at least about 97 percent identity at the 16S rRNA locus or the ITS locus to any of SEQ ID No 1-66.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 1.59302
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15139097', '15271672', '16159536', '15786483', '15400484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6756417577672804
- 35 USC 102 Novelty (BERT): 0.507844157714764
- Combined Prediction Score: 0.6588619977620288
- Mean Citation Score: 243.037438
- Max Citation Score: 265.6539
- Similarity Product: 179.27702182987338

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test